← All trials
NCT06469151
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2024
- Primary completion
- Feb 17, 2025
- Completion date
- Nov 7, 2025
- First posted
- Jun 21, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 84
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.